◼ Archived
Health
🔮 fades ✓
Weight regain after obesity drugs tied to higher odds of suicidal thoughts in observational study
Weight regain after obesity drugs spikes risk of suicidal thoughts, study finds
Obesity Drugs
12 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Obesity Drugs
This hub groups 12 separate news trends connected to Obesity Drugs, spanning June 20, 2026 through September 9, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 104 article observations and 96 source signals, led by Health, Business coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Health
🔮 fades ✓
GLP-1 weight-loss drugs show promise for sleep apnea
GLP-1 weight-loss drugs could cut sleep-apnea rates, opening a new market and clinical pathway for millions.
◼ Archived
Business
🔮 fades ✓
Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future
Investors in Novo Nordisk are on edge as the pharmaceutical giant faces increasing competition in the GLP-1 market.
◼ Archived
Health
🔮 fades ✓
GLP-1s May Be Working in an Entirely Different Way Than We Thought
New research suggests that popular weight-loss drugs may work differently than previously understood.
◼ Archived
Business
🔮 fades ✗
Eli Lilly delays FDA filing for next-generation weight-loss drug retatrutide
Eli Lilly has shifted the FDA application timeline for its next-generation obesity drug, retatrutide, to the first quarter of 2027.
◼ Archived
Health
🔮 fades ✓
Weight-loss drugs didn't improve mental health or job prospects
Recent analyses suggest weight-loss drugs may not deliver broader improvements to mental health, job prospects, or overall quality of life.
◼ Archived
Business
🔮 fades ✓
Why your health plan doesn’t cover GLP-1s, according to a top insurance exec
Insured patients are facing challenges accessing GLP-1 weight-loss drugs as coverage policies and payment models shift.
◼ Archived
Health
🔮 fades ✗
Healthy Returns: Employers aren't expanding coverage of GLP-1 obesity drugs
Employers and public health programs are limiting access to GLP-1 obesity drugs due to rising costs and budget constraints.
◼ Archived
Business
🔮 fades ✗
Eli Lilly's Market Cap Balloons, Again, On This IPO's Setback
Eli Lilly's market value surges as Kailera's weight-loss pill faces market setbacks despite successful clinical efficacy in China.
◼ Archived
Health
🔮 fades ✓
How easy is it to get weight-loss drugs online? Secret shoppers from Yale found out.
A Yale secret shopper study reveals significant gaps in the online prescribing process for GLP-1 obesity medications.
◼ Archived
Business
🔮 fades ✓
Seniors in Medicare are about to get landmark obesity drug coverage
Starting July 1, 2026, Medicare will cover GLP-1 weight-loss drugs for seniors, marking a significant expansion in obesity treatment access.
◼ Archived
Health
🔮 fades ✓
Popular weight-loss drugs linked to unexpected male fertility benefit
Recent data suggests GLP-1 weight-loss medications may provide unexpected fertility benefits for men.